New research suggests that people who stop using new GLP-1 drugs like Wegovy and Mounjaro can put back on reduced body mass much more quickly than those who halt traditional diet and exercise plans.
Findings released in a major health publication demonstrates that while overweight individuals frequently drop substantial amounts of their body weight while on the medication, the weight is regained at an average rate of 0.8 kg per month upon discontinuation.
"Users using these drugs should be informed of the potential of rapid rebound weight gain when the medication is stopped," warns researcher Dr. Susan Jebb.
Such speed of recovery means a return to pre-treatment mass in about a year and a half.
Comparing Therapies
The study, which reviewed 37 of trials involving over 9,000 of participants, contrasted the effects of the injectable medications with other pills.
Researchers point out that individuals who shed pounds through lifestyle changes alone generally have a more gradual weight regain—around 100 grams monthly—after stopping.
Understanding the Rapid Rebound
Nutrition scientists propose the way of the drugs accounts for the accelerated regain.
GLP-1 drugs mimic a body's own chemical called GLP-1, which helps regulate feelings of fullness.
"Artificially providing GLP-1 levels far above than normal could lead to the system to generate a reduced amount of its endogenous hormone, and could reduce responsiveness to its actions," noted Dr. Adam Collins, a dietetics expert.
"Discontinuation of this GLP-1 'fix' leads to appetite is no longer kept in check, making binge eating much more probable."
A Chronic Condition?
Health authorities advise the jabs for people with obesity-related health risks, alongside prescribed lifestyle changes.
Many experts say that, considering the high risk of relapse, the therapy is often ongoing.
This opinion is supported by drug manufacturers, who note that the results "highlight the long-term nature of obesity," similar to managing diseases like hypertension.
Patient Testimonies
Users who have come off the jabs report a intense return of cravings.
"It was like a switch flipping and you're instantly extremely hungry," said a patient.
This challenge is exacerbated if patients have not established lasting lifestyle or habit changes during treatment.
Significant Adoption
Figures indicate that millions of people in the UK have tried weight-loss jabs in the past year, with desire being substantial.
- Adoption is higher among women than men.
- The 40s and 50s demographic shows the greatest level of interest.
- A large proportion access the drugs through private healthcare rather than the NHS.
Finally, clinicians emphasize that while the jabs are potent tools for weight loss, they are not a magic solution and lasting health benefits relies on integrated lifestyle management.
